Down More Than 75% This Year, Should Investors Throw in the Towel on Iovance Biotherapeutics Stock?
Entering trading this week, shares of Iovance Biotherapeutics (NASDAQ: IOVA) have crashed by nearly 78% since the start of the year. It has been an abysmal start to 2025 for a company that does possess some attractive long-term growth prospects.But despite the optimism, a wave of bearishness has taken over, with Iovance's stock in the midst of a deep free fall. What's behind this sell-off, and can this be a good buying opportunity for long-term investors, or are you better off avoiding the stock?Image source: Getty Images.Continue reading
Entering trading this week, shares of Iovance Biotherapeutics (NASDAQ: IOVA) have crashed by nearly 78% since the start of the year. It has been an abysmal start to 2025 for a company that does possess some attractive long-term growth prospects.
But despite the optimism, a wave of bearishness has taken over, with Iovance's stock in the midst of a deep free fall. What's behind this sell-off, and can this be a good buying opportunity for long-term investors, or are you better off avoiding the stock?
Image source: Getty Images.
